ANIP Stock Recent News
ANIP LATEST HEADLINES
Here is how ANI Pharmaceuticals (ANIP) and Galectin Therapeutics Inc. (GALT) have performed compared to their sector so far this year.
It is imperative to build a portfolio of low-beta stocks in a volatile market. ANI Pharmaceuticals, Expand Energy, Avista & Contango are well-poised to gain.
Investors need to pay close attention to ANI Pharmaceuticals (ANIP) stock based on the movements in the options market lately.
IHS, ANIP, MD, FMS and TREE are five stocks with explosive relative price strength.
Unlock your portfolio value with high earnings yield stocks like ANI Pharma, Insteel, Pitney Bowes, IHS Holding and HighPeak Energy.
PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, will host a fireside chat at the 2025 RBC Capital Markets Ophthalmology Virtual Conference as follows:
Five mid-cap stocks have strong revenues and earnings growth potential for 2025. These are: EAT, MAT, CENX, SKYW, ANIP.
ANI (ANIP) possesses solid growth attributes, which could help it handily outperform the market.
ANI Pharmaceuticals, Inc. (ANIP) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ANIP's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
The mean of analysts' price targets for ANI (ANIP) points to a 26.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.